Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine 10 mg safety and tolerability in children with allergic rhinoconjunctivitis or chronic urticaria
2012-003506-27Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bilastine in allergic rhinoconjunctivitis (ARC), chronic urticaria (CU), sponsored by Faes Farma. Started Dec 2012; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)chronic urticaria (CU)
Beyond the preview
Go deeper on 2012-003506-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003506-27.